New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
GAB1 inhibitors impaired migration of chronic lymphocytic leukemia cells and induced apoptosis.
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Researchers sought to determine the recommended dose, safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib in patients with symptomatic untreated CLL.
The primary outcome measure of the trial is to evaluate progression-free survival after LOXO-305 monotherapy compared to investigator’s choice.
The researchers hypothesize that zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
The open-label, nonrandomized phase 3b GREEN trial assessed the safety of obinutuzumab monotherapy or obinutuzumab plus chlorambucil, bendamustine, or fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.